MaxO'DonnellMD
Pulmonology • New York, NYCritical Care Medicine, Pleural Disease
Assistant Professor of Medicine & Public Health
Dr. O'Donnell is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
622 W 168th st
suite E101, PH building
New York, NY 10032Phone+1 212-305-5794
Education & Training
Tufts University School of MedicineClass of 2003
Certifications & Licensure
NY State Medical License 2005 - 2026
MA State Medical License 2006 - 2011
American Board of Internal Medicine Critical Care Medicine- American Board of Internal Medicine Pulmonary Disease
Publications & Presentations
PubMed
- 24 citationsThe value of open-source clinical science in pandemic response: lessons from ISARICAli Abbas, Sheryl Ann Abdukahil, Nurul Najmee Abdulkadir, Ryuzo Abe, Laurent Abel
The Lancet. Infectious Diseases. 2021-12-01 - 11 citationsFrailty subtypes and recovery in older survivors of acute respiratory failure: a pilot study.Matthew R. Baldwin, Lauren R. Pollack, Richard A. Friedman, Simone P Norris, Azka Javaid
Thorax. 2021-04-01 - Operational Research on the Treatment of Drug-Resistant Tuberculosis: Exciting Results That Need to Be ProtectedMax R. O'Donnell, Barun Mathema
American Journal of Respiratory and Critical Care Medicine. 2021-01-01
Grant Support
- Rapid phenotypic detection of complex and emergent TB drug-resistance using a next-generation nanoluciferase reporter phageCOLUMBIA UNIVERSITY HEALTH SCIENCES2023–2028
- Adaptive evaluation of mHealth and conventional adherence support interventions to optimize outcomes with new treatment regimens for drug-resistant tuberculosis and HIV in South AfricaCOLUMBIA UNIVERSITY HEALTH SCIENCES2022–2027
- Nanoluciferase reporter phage for rapid phenotypic characterization of resistance to next-generation antimycobacterial agentsCOLUMBIA UNIVERSITY HEALTH SCIENCES2023–2025
- Nanoluciferase reporter phage for rapid phenotypic characterization of resistance to next-generation antimycobacterial agentsCOLUMBIA UNIVERSITY HEALTH SCIENCES2023–2025
- Nanoluciferase reporter phage for rapid phenotypic characterization of resistance to next-generation antimycobacterial agentsCOLUMBIA UNIVERSITY HEALTH SCIENCES2023–2025
- Nanoluciferase reporter phage for rapid phenotypic characterization of resistance to next-generation antimycobacterial agentsCOLUMBIA UNIVERSITY HEALTH SCIENCES2023–2025
- Advanced Genotypic and Phenotypic monitoring of Drug Resistant TB to Improve TB Treatment OutcomesALBERT EINSTEIN COLLEGE OF MEDICINE2015–2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
